Literature DB >> 26116252

Self-reported hepatitis A vaccination as a predictor of hepatitis A virus antibody protection in U.S. adults: National Health and Nutrition Examination Survey 2007-2012.

Maxine M Denniston1, R Monina Klevens2, Ruth B Jiles3, Trudy V Murphy4.   

Abstract

OBJECTIVES: To estimate the predictive value of self-reported hepatitis A vaccine (HepA) receipt for the presence of hepatitis A virus (HAV) antibody (anti-HAV) from either past infection or vaccination, as an indicator of HAV protection.
METHODS: Using 2007-2012 National Health and Nutrition Examination Survey data, we assigned participants to 4 groups based on self-reported HepA receipt and anti-HAV results. We compared characteristics across groups and calculated three measures of agreement between self-report and serologic status (anti-HAV): percentage concordance, and positive (PPV) and negative (NPV) predictive values. Using logistic regression we investigated factors associated with agreement between self-reported vaccination status and serological results.
RESULTS: Demographic and other characteristics varied significantly across the 4 groups. Overall agreement between self-reported HepA receipt and serological results was 63.6% (95% confidence interval [CI] 61.9-65.2); PPV and NPV of self-reported vaccination status for serological result were 47.0% (95% CI 44.2-49.8) and 69.4% (95% CI 67.0-71.8), respectively. Mexican American and foreign-born adults had the highest PPVs (71.5% [95% CI 65.9-76.5], and 75.8% [95% CI 71.4-79.7]) and the lowest NPVs (21.8% [95% CI 18.5-25.4], and 20.0% [95% CI 17.2-23.1]), respectively. Young (ages 20-29 years), US-born, and non-Hispanic White adults had the lowest PPVs (37.9% [95% CI 34.5-41.5], 39.1% [95% CI, 36.0-42.3], and 39.8% [36.1-43.7]), and the highest NPVs (76.9% [95% CI 72.2-81.0, 78.5% [95% CI 76.5-80.4)], and 80.6% [95% CI 78.2-82.8), respectively. Multivariate logistic analyses found age, race/ethnicity, education, place of birth and income to be significantly associated with agreement between self-reported vaccination status and serological results.
CONCLUSIONS: When assessing hepatitis A protection, self-report of not having received HepA was most likely to identify persons at risk for hepatitis A infection (no anti-HAV) among young, US-born and non-Hispanic White adults, and self-report of HepA receipt was least likely to be reliable among adults with the same characteristics.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Concordance; Hepatitis A vaccine (HepA); Predictive value; Self-report; Serological testing; Vaccination status

Mesh:

Substances:

Year:  2015        PMID: 26116252      PMCID: PMC4568740          DOI: 10.1016/j.vaccine.2015.06.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults.

Authors:  Niel Hens; Aklilu Habteab Ghebretinsae; Karin Hardt; Pierre Van Damme; Koen Van Herck
Journal:  Vaccine       Date:  2014-02-07       Impact factor: 3.641

2.  Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1999-10-01

3.  Strategy for hepatitis A seroprevalence survey in a population of young people.

Authors:  Michele Mongillo; Federica Chiara; Maddalena Ranzato; Andrea Trevisan
Journal:  Vaccine       Date:  2010-08-21       Impact factor: 3.641

4.  Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States.

Authors:  I R Willner; M D Uhl; S C Howard; E Q Williams; C A Riely; B Waters
Journal:  Ann Intern Med       Date:  1998-01-15       Impact factor: 25.391

5.  Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Anthony E Fiore; Annemarie Wasley; Beth P Bell
Journal:  MMWR Recomm Rep       Date:  2006-05-19

6.  Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Authors: 
Journal:  MMWR Recomm Rep       Date:  1996-12-27

7.  Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study.

Authors:  Helena H Askling; Lars Rombo; Ronald van Vollenhoven; Ingemar Hallén; Åke Thörner; Margareta Nordin; Christian Herzog; Anu Kantele
Journal:  Travel Med Infect Dis       Date:  2014-01-29       Impact factor: 6.211

8.  Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.

Authors:  J P Bryan; M Nelson
Journal:  Arch Intern Med       Date:  1994-03-28

9.  Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-10-19       Impact factor: 17.586

10.  Outbreak of hepatitis A in the USA associated with frozen pomegranate arils imported from Turkey: an epidemiological case study.

Authors:  Melissa G Collier; Yury E Khudyakov; David Selvage; Meg Adams-Cameron; Erin Epson; Alicia Cronquist; Rachel H Jervis; Katherine Lamba; Akiko C Kimura; Rick Sowadsky; Rashida Hassan; Sarah Y Park; Eric Garza; Aleisha J Elliott; David S Rotstein; Jennifer Beal; Thomas Kuntz; Susan E Lance; Rebecca Dreisch; Matthew E Wise; Noele P Nelson; Anil Suryaprasad; Jan Drobeniuc; Scott D Holmberg; Fujie Xu
Journal:  Lancet Infect Dis       Date:  2014-09-03       Impact factor: 25.071

View more
  1 in total

Review 1.  Epidemiology and Transmission of Hepatitis A Virus and Hepatitis E Virus Infections in the United States.

Authors:  Megan G Hofmeister; Monique A Foster; Eyasu H Teshale
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.